Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and Symptomatology.

Barry A, Cronin O, Ryan AM, Sweeney B, Yap SM, O'Toole O, Allen AP, Clarke G, O'Halloran KD, Downer EJ.

Front Physiol. 2016 Jun 2;7:194. doi: 10.3389/fphys.2016.00194. eCollection 2016. Review.

2.

IL-10 Modulates Th17 Pathogenicity during Autoimmune Diseases.

Guo B.

J Clin Cell Immunol. 2016 Apr;7(2). pii: 400. Epub 2016 Mar 22.

3.

Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications.

Dos Passos GR, Sato DK, Becker J, Fujihara K.

Mediators Inflamm. 2016;2016:5314541. doi: 10.1155/2016/5314541. Epub 2016 Jan 28. Review.

4.

Glatiramer acetate treatment negatively regulates type I interferon signaling.

Molnarfi N, Prod'homme T, Schulze-Topphoff U, Spencer CM, Weber MS, Patarroyo JC, Lalive PH, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2015 Nov 9;2(6):e179. doi: 10.1212/NXI.0000000000000179. eCollection 2015 Dec. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2015 Dec;2(6):e189.

5.

Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.

Tao Y, Zhang X, Zivadinov R, Dwyer MG, Kennedy C, Bergsland N, Ramasamy D, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B, Markovic-Plese S.

Neurol Neuroimmunol Neuroinflamm. 2015 Nov 12;2(6):e176. doi: 10.1212/NXI.0000000000000176. eCollection 2015 Dec.

6.

Type I IFNs Act upon Hematopoietic Progenitors To Protect and Maintain Hematopoiesis during Pneumocystis Lung Infection in Mice.

Prigge JR, Hoyt TR, Dobrinen E, Capecchi MR, Schmidt EE, Meissner N.

J Immunol. 2015 Dec 1;195(11):5347-57. doi: 10.4049/jimmunol.1501553. Epub 2015 Oct 30.

PMID:
26519535
7.

TIR Domain-Containing Adapter-Inducing Beta Interferon (TRIF) Mediates Immunological Memory against Bacterial Pathogens.

Kanagavelu S, Flores C, Termini JM, Romero L, Riveron R, Ruiz J, Arditi M, Schesser K, Fukata M.

Infect Immun. 2015 Nov;83(11):4404-15. doi: 10.1128/IAI.00674-15. Epub 2015 Sep 8.

8.

Role of TRIF Small Interference RNA (siRNA) in Chronic Experimental Allergic Encephalomyelitis (EAE).

Wang X, Zheng X, Ma C, Zhao L.

Med Sci Monit. 2015 Sep 1;21:2583-7. doi: 10.12659/MSM.894564.

9.

IFNAR signaling directly modulates T lymphocyte activity, resulting in milder experimental autoimmune encephalomyelitis development.

Kavrochorianou N, Evangelidou M, Markogiannaki M, Tovey M, Thyphronitis G, Haralambous S.

J Leukoc Biol. 2016 Jan;99(1):175-88. doi: 10.1189/jlb.3A1214-598R. Epub 2015 Jul 31.

PMID:
26232452
10.

Analysis of Th17 and Tc17 Frequencies and Antiviral Defenses in Gut-Associated Lymphoid Tissue of Chronic HIV-1 Positive Patients.

d'Ettorre G, Ceccarelli G, Andreotti M, Selvaggi C, Giustini N, Serafino S, Schietroma I, Nunnari G, Antonelli G, Vullo V, Scagnolari C.

Mediators Inflamm. 2015;2015:395484. doi: 10.1155/2015/395484. Epub 2015 Jun 28.

11.

Salmonella Typhimurium Co-Opts the Host Type I IFN System To Restrict Macrophage Innate Immune Transcriptional Responses Selectively.

Perkins DJ, Rajaiah R, Tennant SM, Ramachandran G, Higginson EE, Dyson TN, Vogel SN.

J Immunol. 2015 Sep 1;195(5):2461-71. doi: 10.4049/jimmunol.1500105. Epub 2015 Jul 22.

PMID:
26202980
12.

Differential effects of IFN-β on IL-12, IL-23, and IL-10 expression in TLR-stimulated dendritic cells.

Yen JH, Kong W, Hooper KM, Emig F, Rahbari KM, Kuo PC, Scofield BA, Ganea D.

J Leukoc Biol. 2015 Nov;98(5):689-702. doi: 10.1189/jlb.3HI0914-453R. Epub 2015 Jun 9.

PMID:
26059829
13.

Interferon-β suppresses murine Th1 cell function in the absence of antigen-presenting cells.

Boivin N, Baillargeon J, Doss PM, Roy AP, Rangachari M.

PLoS One. 2015 Apr 17;10(4):e0124802. doi: 10.1371/journal.pone.0124802. eCollection 2015.

14.

Induction of endogenous Type I interferon within the central nervous system plays a protective role in experimental autoimmune encephalomyelitis.

Khorooshi R, Mørch MT, Holm TH, Berg CT, Dieu RT, Dræby D, Issazadeh-Navikas S, Weiss S, Lienenklaus S, Owens T.

Acta Neuropathol. 2015 Jul;130(1):107-18. doi: 10.1007/s00401-015-1418-z. Epub 2015 Apr 14.

15.

No quiet surrender: molecular guardians in multiple sclerosis brain.

Steinman L.

J Clin Invest. 2015 Apr;125(4):1371-8. doi: 10.1172/JCI74255. Epub 2015 Apr 1. Review.

16.

Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.

Börnsen L, Romme Christensen J, Ratzer R, Hedegaard C, Søndergaard HB, Krakauer M, Hesse D, Nielsen CH, Sorensen PS, Sellebjerg F.

PLoS One. 2015 Mar 4;10(3):e0118830. doi: 10.1371/journal.pone.0118830. eCollection 2015.

17.
18.

Immunomodulatory activity of interferon-beta.

Kasper LH, Reder AT.

Ann Clin Transl Neurol. 2014 Aug;1(8):622-31. doi: 10.1002/acn3.84. Epub 2014 Jul 23. Review.

19.

The C5a anaphylatoxin receptor (C5aR1) protects against Listeria monocytogenes infection by inhibiting type 1 IFN expression.

Calame DG, Mueller-Ortiz SL, Morales JE, Wetsel RA.

J Immunol. 2014 Nov 15;193(10):5099-107. doi: 10.4049/jimmunol.1401750. Epub 2014 Oct 8.

20.

Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis.

Harari D, Kuhn N, Abramovich R, Sasson K, Zozulya AL, Smith P, Schlapschy M, Aharoni R, Köster M, Eilam R, Skerra A, Schreiber G.

J Biol Chem. 2014 Oct 17;289(42):29014-29. doi: 10.1074/jbc.M114.602474. Epub 2014 Sep 5.

Items per page

Supplemental Content

Write to the Help Desk